Leaders and officials with Takeda Pharmaceutical Company Limited recently highlighted their sustained commitment to fighting Hodgkin lymphoma at the 10th International Symposium on Hodgkin Lymphoma (ISHL) in Germany.
At this latest symposium, representatives from Takeda Pharmaceutical -- which is a Jubilee sponsor of the event -- emphasized a variety of scientific updates about Adcetris.
One presentation shows data for patients who have refractory or relapsed Hodgkin lymphoma but do not qualify for stem cell transplantation or multi-agent chemotherapy. This is the first time this kind of research will be presented.
“The data to be presented at this year’s ISHL are a proof point of the excellent progress we have made in furthering the clinical program of brentuximab vedotin,” Dr. Dirk Huebner, executive medical director at the Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company, said. “Through our robust ongoing clinical investigation program, we have continued to see benefit of brentuximab vedotin, particularly in patients with Hodgkin lymphoma or other CD30-positive malignancies who would typically face a poor prognosis. We remain committed to bringing this important therapy to all patients who might benefit from it.”
All of the presentations will show the important scientific progress that has been made for patients living with Hodgkin lymphoma.
